ロード中...
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
BACKGROUND: Nivolumab is an immune checkpoint inhibitor targeting the programmed death-1 receptor that improves survival in a subset of patients with clear cell renal cell carcinoma (ccRCC). In contrast to other tumor types that respond to immunotherapy, factors such as programmed death ligand-1 (PD...
保存先:
| 出版年: | J Immunother Cancer |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMJ Publishing Group
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7931766/ https://ncbi.nlm.nih.gov/pubmed/33658305 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001506 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|